To include your compound in the COVID-19 Resource Center, submit it here.

Lexgenleucel-T: Phase II data

A Phase II trial showed that 10 of 48 patients who received Lexgenleucel-T had circulating

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE